Phase 1 N=24 Thrombosomes® in Bleeding Thrombocytopenic Patients
Thrombocytopenia · Hematologic Diseases · Bone Marrow Aplasia
Primary: Number of Patients With Treatment-Emergent Adverse Events (TEAE) — 7; 6; 5 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=97 Prospective Study of Patients With Thrombocytopenia Following HSCT
Thrombocytopenia · Hematologic Diseases
Primary: Number of Participants With Platelet Count Recovery — 20; 22; 6 Participants
Phase 3 N=1,351 Optimal Platelet Dose Strategy for Management of Thrombocytopenia
Thrombocytopenia
Primary: At Least One Day With Grade 2 or Higher Bleeding — 304; 293; 299; 142 participants — p=0.83
Phase 3 N=203 Long-term Study of Romiplostim in Thrombocytopenic Pediatric Patients With Immune Thrombocytopenia (ITP)
Immune Thrombocytopenia
Primary: Percentage of Time With a Platelet Response During the First 6 Months of Treatment — 50.00 percentage of time
Phase 2 N=16 Amgen Megakaryopoiesis Protein 2 (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP)
Thrombocytopenic Purpura
Primary: Number of Participants With Adverse Events — 4; 4; 7; 1 Participants
Phase 3 N=407 An Open Label Study of Romiplostim in Adult Thrombocytopenic Subjects With ITP
Idiopathic Thrombocytopenic Purpura · Thrombocytopenia · Thrombocytopenic Purpura
Primary: Adverse Events — 162; 215 participants
Phase 3 N=62 Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients
Idiopathic Thrombocytopenic Purpura · Thrombocytopenia · Thrombocytopenia in Pediatric Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
Primary: Percentage of Participants With a Durable Platelet Response — 10.0; 52.4 percentage of participants — p=0.0018
Phase 2 N=60 Study of Romiplostim for Chemotherapy Induced Thrombocytopenia
Isolated Chemotherapy-induced Thrombocytopenia
Primary: Percentage of Participants Who Achieved Platelet Counts of ≥ 100,000/mcL — 93 percentage of participants
Phase 3 N=330 American Trial Using Tranexamic Acid in Thrombocytopenia
Thrombocytopenia
Primary: Bleeding Within 30 Days — 73; 78 Participants
Phase 3 N=102 A Trial of Antenatal Treatment of Alloimmune Thrombocytopenia
Alloimmune Thrombocytopenia · Fetal Alloimmune Thrombocytopenia
Primary: Number of Newborns With a Birth Platelet Count > 50,000/uL — 48; 47 number of newborns with >50,000 pets
Phase 3 N=57 Treatment of Chronic Immune Thrombocytopenic Purpura (ITP) With Intravenous Immunoglobulin IgPro10
Immune Thrombocytopenic Purpura
Primary: Platelet Response — 80.7 Percent of participants
Phase 2 N=122 A Study of MabThera (Rituximab) in Patients With Idiopathic Thrombocytopenic Purpura.
Idiopathic Thrombocytopenic Purpura
Primary: Percentage of Participants Achieving a Complete Hematological Response (CR) or Confirmed Partial Hematological Response (PR) — 43.5 percentage of participants
Phase 3 N=64 IGIV Study for Chronic ITP Patients Ages 3-70
Idiopathic Thrombocytopenic Purpura
Primary: Response Rate — 81.3 percentage of responders
Phase 3 N=145 Phase III Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura
Acquired Thrombotic Thrombocytopenic Purpura
Primary: Time to Platelet Count Response — 2.69; 2.88 days — p== 0.0099
Phase 2 N=19 Low Dose Rituximab in Thrombotic Thrombocytopenic Purpura
Thrombotic Thrombocytopenic Purpura
Primary: Incidence of the Composite Primary Outcome of Exacerbation or Refractory TTP — 2; 0 Participants
Phase 2 N=41 A Study of TAK-079 in Adults With Persistent/Chronic Primary Immune Thrombocytopenia
Primary Immune Thrombocytopenia
Primary: Percentage of Participants With at Least One Grade 3 or Higher Treatment Emergent Adverse Event (TEAE), Treatment Emergent Serious Adverse Event (SAE), and TEAEs Leading…
Phase 3 N=66 A Study Evaluating the Safety and Efficacy of Long-term Dosing of Romiplostim in Thrombocytopenic Pediatric Patients With Immune (Idiopathic) Thrombocytopenia Purpura
Thrombocytopenia in Pediatric Subjects With Immune Idiopathic Thrombocytopenic Purpura ITP
Primary: Number of Participants With Adverse Events — 64; 19; 2; 1 Participants
Phase 3 N=92 Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platelet Counts That Can Lead to Bruising Easily, Bleeding Gums, and/or Bleeding Inside the Body.
Idiopathic Thrombocytopenic Purpura
Primary: Number of Participants Achieving a Platelet Count >=50 Giga Cells Per Liter (Gi/L) for at Least 6 Out of 8 Weeks, Between Weeks 5 and 12 of Part 1 — 1; 25 Participants…
Phase 2 N=10 Complement Inhibition Using Eculizumab to Overcome Platelet Transfusion Refractoriness in Patients With Severe Thrombocytopenia
Thrombocytopenia · Alloimmune Platelet Refractoriness
Primary: Number of Subjects With Sustained Platelet Transfusion Responsiveness — 4 Participants
N/A N=445 Platelet Count Trends in Pre-eclamptic Parturients
Obstetric Labor Complications · Preeclampsia · Thrombocytopenia
Primary: Positive Predictive Value of Earliest Available Platelet Count — 99; 90; 100 percentage of positive platelet counts
Phase 2 N=60 Eltrombopag for Post Transplant Thrombocytopenia
Thrombocytopenia
Primary: Comparing the Efficacy of Eltrombopaq and Placebo — 15; 5; 9; 0 Participants
Phase 2 N=65 Chronic Hepatitis C Virus Related Thrombocytopenia to Evaluate the Effects of E5501
Thrombocytopenia
Primary: Number of Participants Who Achieved Platelet Response (Greater Than or Equal to 100 x 10^9/L) by Day 21 of Treatment Period A1 of Core Study — 1; 6; 12; 9 Participants…
Phase 3 N=165 Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer
Chemotherapy-induced Thrombocytopenia
Primary: Percentage of Participants Who Had Thrombocytopenia-induced Dose Modification — 84.4; 35.7 percentage of participants — p=< 0.001
Phase 3 N=34 P3 Study to Evaluate Efficacy and Safety of AMG 531 in Thrombocytopenic Japanese Subjects With Immune (Idiopathic) Thrombocytopenic Purpura
Idiopathic Thrombocytopenic Purpura
Primary: Weeks With Weekly Platelet Response — 0.0; 11.0 Weeks — p=<0.0001
Phase 3 N=231 Treatment of Thrombocytopenia in Patients With Chronic Liver DiseaseUndergoing an Elective Procedure
Thrombocytopenia Associated With Liver Disease
Primary: Percentage of Participants Who Did Not Require a Platelet Transfusion or Any Rescue Procedure for Bleeding After Randomization Following a Scheduled Procedure — 22.9…
Phase 3 N=204 Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing an Elective Procedure
Thrombocytopenia Associated With Liver Disease
Primary: Percentage of Participants Who Did Not Require a Platelet Transfusion After Randomization and up to 7 Days Following a Scheduled Procedure — 34.9; 68.6; 33.3; 87.9…
Phase 2 N=45 Evaluating the Safety and Efficacy of Romiplostim (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP)
Idiopathic Thrombocytopenic Purpura
Primary: Number of Participants With Adverse Events — 4; 4; 4; 4 Participants
Phase 2 N=12 Efficacy of Eltrombopag to Improve Thrombocytopenia of MYH9-related Disease
Blood Platelet Disorders
Primary: Response to Drug Based on Platelet Count at the End of Therapy — 91.6 percentage of participants
Phase 2 N=77 Validation of a Predictive Model of Response to Romiplostim in Patients With IPSS Low or Intermediate-1 Risk MDS and Thrombocytopenia
Myelodysplastic Syndromes
Primary: Hematologic Improvement of Platelets (HI-P) After 4 Months on Therapy — 71.75; 18.75 platelets (/nL)
Phase 4 N=146 A Study of Anagrelide and Hydroxyurea in High-Risk Essential Thrombocythemia Patients
Thrombocythemia, Hemorrhagic
Primary: Change From Baseline in Left Ventricular Ejection Fraction (LVEF) Over Time — 66.4; 66.9; 0.5; -1.1 percentage of ejection fraction